Regenerex Pharma (RGPX) Return on Equity ROE from the second quarter 2025 to second quarter 2024 and annually, average high and low, overall ranking from Sep 30 2025 to Sep 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
REGENEREX PHARMA, INC.  (OTC: RGPX)

Regenerex Pharma's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Regenerex Pharma in the second quarter 2025?
Due to the lack of equity, it was not possible to calculate Regenerex Pharma, Inc.'s return on equity (ROE) in its second quarter 2025

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2025)
II. Quarter		 (Jun 30 2025)
I. Quarter		 (Mar 31 2025)
IV. Quarter		 (Dec 31 2024)
III. Quarter		 (Sep 30 2024)
II. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -1 -1 -1 -4 -4
Return On Equity (TTM) - - - - -
RGPX's Total Ranking # # # # #
Equity (TTM) in Millions -5 -5 -4 -5 -5
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to RGPX Management Effectiveness >> RGPX's 5 Years Annual ROE >> Compare RGPX ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





RGPX Annual Return On Equity (Mar 31 2025)
2023		 (Mar 31 2022)
2022		 (Mar 31 2021)
2020		 (Mar 31 2020)
2019		 (Mar 31 2019)
2018
Total Equity in Millions -4 -1 -1 -1 0
Y / Y Equity Change - - - - -
Net Income in Millions -3 0 0 0 0
Y / Y Net Income Change - - 217.03 % 19.23 % 88.33 %
Return On Equity - - - - -

Back to RGPX Management Effectiveness >> RGPX's 5 Years Annual ROE >> Compare RGPX ROE to its Competitors




Annual Roe Comment
Despite deterioration in net income, company improved ROE to in 2023, company improved ROE to 88.33 % compared to the prior year.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
RGPX's' Return on Equity at Yahoo Finance
RGPX's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for RGPX's Competitors
Subscribers only: Roe for Regenerex Pharma's Suppliers
Subscribers only: Return On Equity for RGPX's Customers




Companies with similar Return On Equity at Sep 30 2025, within Healthcare Sector ROE
Abeona Therapeutics Inc   78.38 %
3m Company  78.34 %
Capforce Inc   78.18 %
Organon and Co   75.54 %
Cormedix Inc   75.37 %
Exelixis Inc   72.41 %
Earth Science Tech Inc   72.38 %
Idexx Laboratories Inc  67.78 %
Nrc Health  67.76 %
Dariohealth Corp   59.47 %
Medinotec Inc   57.47 %
Exagen Inc   54.81 %
Adma Biologics Inc   53.98 %
Zoetis Inc   51.91 %
Concentra Group Holdings Parent Inc   47.90 %
Cytomx Therapeutics Inc   44.49 %
Zevra Therapeutics Inc   42.68 %
Agilent Technologies inc   41.86 %
Gilead Sciences Inc   40.87 %
Entera Bio Ltd   40.47 %
Tenet Healthcare Corp  39.99 %
Merck and Co Inc   38.92 %
Longduoduo Co Ltd  36.66 %
Puma Biotechnology Inc   36.14 %
Sbc Medical Group Holdings Incorporated  35.54 %
Siga Technologies Inc  35.26 %
Bristol myers Squibb Company  34.59 %
Sab Biotherapeutics Inc   33.39 %
Johnson and Johnson  32.69 %
Acadia Pharmaceuticals Inc   32.27 %

Date modified: 2026-09-12T06:28:46+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.